Nova Mentis is the latest biotech to enter the psychedelic space, initiating a Phase IIa trial testing psilocybin in fragile X syndrome.

Canada-based Nova Mentis is now recruiting patients for a 28-day study testing oral microdoses of psilocybin in 10 patients with fragile X syndrome, the leading genetic cause of autism spectrum disorder. The study will take place in a facility of the CRO KGK Sciences in London, Ontario, Canada.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase IIa study will test the safety and efficacy of the psilocybin formulation NM-1001 administered every other day for 28 days. Nova Mentis will explore the effects of NM-1001 on behavioural symptoms using diagnostic tests based on mRNA and serotonin biomarker technology, combined with artificial intelligence (AI).

The Phase IIa trial design has approval from Health Canada, a regulatory body that has shown willingness to approve studies testing psychedelic therapies. Nova Mentis and KGK plan to treat the first patient in Q2 2023 and expect preliminary data later this year.

Psilocybin in fragile X syndrome

Fragile X syndrome causes mutations in the gene Fragile X Messenger Ribonucleoprotein 1 (FMR1), leading to a life-long disorder associated with a spectrum of developmental, intellectual, and behavioural challenges. There are no cures for fragile X syndrome, though are many treatments available for symptoms and a robust drug development pipeline.

Psilocybin, which is the main psychoactive ingredient found in psychedelic fungi known as magic mushrooms, is a type of serotonin agonist. The Nova Mentis website states that psilocybin could mimic serotonergic signalling to help compensate for low serotonin levels common in development disorders like fragile X syndrome and autism spectrum disorder.

Nova Mentis’s Phase IIa trial will use oral microdoses of psilocybin that are approximately one-tenth of a normal dose. Shifting regulatory and clinical perspectives have led to a recent surge in clinical trials testing psychedelics, though most data is from early-stage clinical trials.